|Bid||13.75 x 800|
|Ask||21.21 x 4000|
|Day's Range||18.43 - 19.22|
|52 Week Range||11.65 - 49.12|
|PE Ratio (TTM)||1.04|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.74|
Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.
LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
BioDelivery Sciences International, Inc. (BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
STAINES-UPON-THAMES, United Kingdom , May 14, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, June 12, 2018 , ...
The Surrey, Britain-based company said it had a loss of 21 cents per share. Earnings, adjusted for one-time gains and costs, were $1.31 per share. The results exceeded Wall Street expectations. The average ...
-- Net sales of $572.6 million driven by strong hospital products performance -- -- GAAP¹ diluted loss per share from continuing operations of $0.50 , adjusted diluted earnings per share of $1.31 -- -- ...
The "60 Minutes" report looked at how businesses across the health care supply chain have come to benefit from higher drug prices. The report, which ran on CBS on Sunday, focused on a lawsuit filed by the city of Rockford, Illinois, claiming two young patients treated with Mallinckrodt's drug, HP Acthar Gel, faced a bill of half a million dollars. A "60 Minutes" investigation has put the price of one of Mallinckrodt's drugs under the microscope, but it isn't weighing on the pharmaceutical giant's stock price.
Experienced traders know that rumors don’t have to be true to move markets. Ever since a 2015 “60 Minutes” expose linking Lumber Liquidators Holdings Inc (NYSE: LL ) products to cancer sent the stock crashing ...
STAINES-UPON-THAMES, United Kingdom , May 7, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), in response to a segment aired on CBS' 60 Minutes on Sunday, May 6 , has posted facts related ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
STAINES-UPON-THAMES, United Kingdom, May 3, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today expressed disappointment that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee recommended in a vote of 21 to 3 that the risk-benefit profile of stannsoporfin does not support approval for the treatment of newborns ≥35 weeks of gestational age with indicators of hemolysis who are at risk of developing hyperbilirubinemia (severe jaundice). Mallinckrodt appreciates the committees' review and discussion of stannsoporfin, and will work closely with the FDA as the review process continues. Given the outcome of today's meeting, the company is evaluating alternatives for this development program.
STAINES-UPON-THAMES, United Kingdom , April 20, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, May 22, 2018 ...
The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic. The Drug Enforcement Administration's proposed changes to its regulations over addictive drug manufacturing quotas were announced by Attorney General Jeff Sessions. The plan could sharply reduce the annual production of painkillers.
-- Company repays debt maturing April 2018 with cash on hand -- STAINES-UPON-THAMES, United Kingdom , April 16, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical ...
The lawsuit claims Mallinckrodt continued to raise the price of Acthar despite knowing what was in it.
STAINES-UPON-THAMES, United Kingdom , April 9, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, May 9, 2018, ...
STAINES-UPON-THAMES, United Kingdom, April 4, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced it has nominated two new members for its Board of Directors. Both Paul R. Carter and Anne C. Whitaker have extensive experience in the branded pharmaceutical industry and will join the Mallinckrodt Board pending shareholder vote at the Annual General Meeting in May, 2018. For more than 25 years, Mr. Carter, age 57, has held a variety of leadership roles in the biopharmaceutical industry, serving as executive vice president, commercial operations of Gilead Sciences, Inc. from 2014 to 2016, and senior vice president and head, international commercial operations from 2006 to 2014.
STAINES-UPON-THAMES, United Kingdom, April 4, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that Angus Russell will succeed Melvin Booth as non-executive chairman of the Company's Board of Directors when Mr. Booth retires from the Board in May 2018. A director, member of the Audit and Portfolio Committees and chairman of the Mallinckrodt Board since June 2013, Mr. Booth, age 73, has elected to retire. Commenting on his decision, Mr. Booth said, "It has been a tremendous privilege to serve on the Mallinckrodt Board of Directors since the company became public in 2013, and a particular honor to serve as chairman.
Callers will need to provide the Conference ID of 2886785. All callers will be required to provide the Conference ID of 2886785. Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies.